Skip to Main Content

The YODA ProjectThe YODA Project

    • Welcome
      • Policies
      • Development
      • Due Diligence Assessment
      • Data Use Agreement
      • Data Expiration
    • Project Leadership
    • Steering Committee
    • Roles & Responsibilities
      • Partnering with the YODA Project
        • Overview
        • Available Data
        • Data Release Pilot Project
      • Johnson & Johnson Consumer Inc. (a subsidiary of Kenvue, Inc.)
        • Overview
        • Systematic Reviews
        • Approved Data Requests
      • QMUL
      • SI-BONE
    • Publications & Presentations
    • Announcements & Media Coverage
    • Relevant Literature
      • YODA Project Steering Committee and Stakeholders Conference
      • University College London and YODA Project Joint Meeting on Facilitating Data Access to Non-Industry Funded Research
    • Community Data Sharing Resources
    • FAQs
    • Acknowledgements
    • Contact Us
      • How To
      • Conflict of Interest
      • Data Use Agreement Training
    • Data Request Review Process
    • Request CSR Summary
    • Approved Data Requests
  • Trials
  • My Dashboard
    • YODA Project Metrics
      • Submitted Requests to Use Johnson & Johnson Data
      • Details of Data Requests
      • Clinical Trial Inquiries and CSR Summary Requests
      • Trials Determined to be Unavailable
  • Log in

Rabies

NCT01228383 – A Randomized, Single-blind, Active-controlled, Mono-center Phase II Study to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Purified Vero Cell Rabies Vaccine vs. Human Rabies Immune Globulin or Placebo in Combination With Purified Vero Cell Rabies Vaccine vs. CL184 or Placebo in Combination With Human Diploid Cell Rabies Vaccine in Healthy Adult Subjects

Posted on March 30, 2017 by tsuperadmin -

NCT00708084 – A Single-blind, Randomized, Monocentric Phase II Trial to Explore the Safety and Rabies-neutralizing Activity of Combined Administration of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin Plus Rabies Vaccine in Simulated Rabies Post-exposure Prophylaxis in Children and Adolescents

Posted on March 30, 2017 by tsuperadmin -

NCT00656097 – A Randomized, Single-blind, Controlled, Monocentric Phase II Trial to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects

Posted on March 30, 2017 by tsuperadmin -

Side navigation

Site Map
Yale University logo
CORE - Center for outcomes, research, and evaluation Logo
  • Visit the YODA Project on Facebook
  • Visit the YODA Project on X

Accessibility at Yale

website designed by Gravity Switch